Vita 34 AG - Stock Quote VTIAF
Morningstar's Vita 34 AG Stock Analysis
1-Star Price
PREMIUM
5-Star Price
PREMIUM
Economic Moat
PREMIUM
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible for overseeing the methodology that supports the quantitative fair value. As an employee of Morningstar, Inc., Mr. Davidson is guided by Morningstar, Inc.'s Code of Ethics and Personal Securities Trading Policy in carrying out his responsibilities. For information regarding Conflicts of Interests, click here .
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Vita 34 AG's Company Profile
Vita 34 AG is an umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The organization operates in the business segment of Stem Cell Banking, which is active in the field of collecting, processing and storing stem cells from umbilical cord blood and tissue, as well as the development of cell therapy processes. It operates in Germany, Spain, and other international countries, of which maximum revenue is derived from the business operations in Germany.